The role of N-acetylcysteine in the management of acute and chronic pulmonary complications of sulfur mustard: a literature review

References

• Afaq F, Abidi P, Rahman Q. (2000). N-acetyl l-cysteine attenuates oxidant-mediated toxicity induced by chrysotile fibers. Toxicol Lett 117:53–60
   PubMed Web of Science ®Google Scholar
• Aitio ML. (2006). N-acetylcysteine – passe-partout or much ado about nothing? Br J Clin Pharmacol 61:5–15
   PubMed Web of Science ®Google Scholar
• Akdur O, Sozuer EM, Ikizceli I, et al. (2008). Experimental inhalation of chlorine gas produced with a different method: effects of N-acetyl cysteine on acute pulmonary damage. Toxicol Mech Methods 18:739–43
   PubMed Web of Science ®Google Scholar
• Allon N, Amir A, Manisterski E, et al. (2009). Inhalation exposure to sulfur mustard in the guinea pig model: clinical, biochemical and histopathological characterization of respiratory injuries. Toxicol Appl Pharmacol 241:154–62
   PubMed Web of Science ®Google Scholar
• Alsop JA. (2012). Managing drug overdoses and poisonings. In: Alldredge BK, Corelli RL, Ernst ME, et al. (eds.) Koda-Kimble and Young's applied therapeutics: the clinical use of drugs. Philadelphia, PA: Lippincott Williams & Wilkins, 85
   Google Scholar
• Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. (2011). Immunomodulatory effects of macrolide antibiotics – part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 81:75–87
   PubMedGoogle Scholar
• Anderson DR, Byers SL, Vesely KR. (2000). Treatment of sulfur mustard (HD)-induced lung injury. J Appl Toxicol Suppl 1:S129–32
   Google Scholar
• Arfsten DP, Johnson EW, Wilfong ER, et al. (2007). Distribution of radio-labeled N-acetyl-l-cysteine in Sprague-Dawley rats and its effect on glutathione metabolism following single and repeat dosing by oral gavage. Cutan Ocul Toxicol 26:113–34
   PubMed Web of Science ®Google Scholar
• Atkins KB, Lodhi IJ, Hurley LL, Hinshaw DB. (2000). N-acetylcysteine and endothelial cell injury by sulfur mustard. J Appl Toxicol 20:S125–8
   PubMedGoogle Scholar
• Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. (2007). N-Acetylcysteine – a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 7:355–9
   PubMed Web of Science ®Google Scholar
• Balali-Mood M, Hefazi M. (2005). The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam Clin Pharmacol 19:297–315
   PubMed Web of Science ®Google Scholar
• Bobb AJ, Arfsten DP, Jederberg WW. (2005). N-acetyl-l-cysteine as prophylaxis against sulfur mustard. Mil Med 170:52–6
   PubMed Web of Science ®Google Scholar
• Bonanomi L, Gazzaniga A. (1980). Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis Suppl 111:45–51
   PubMedGoogle Scholar
• Childs A, Jacobs C, Kaminski T, et al. (2001). Supplementation with vitamin C and N-acetyl-cysteine increases oxidative stress in humans after an acute muscle injury induced by eccentric exercise. Free Radic Biol Med 31:745–53
   PubMed Web of Science ®Google Scholar
• Cowan FM, Anderson DR, Broomfield CA, et al. (1997). Biochemical alterations in rat lung lavage fluid following acute sulfur: II. Increase in proteolytic activity. Inhal Toxicol 9:53–61
   Web of Science ®Google Scholar
• Cowan FM, Broomfield CA, Smith WJ. (1992). Inhibition of sulfur mustard-increased protease activity by niacinamide, N-acetyl-l-cysteine or dexamethasone. Cell Biol Toxicol 8:129–38
   PubMed Web of Science ®Google Scholar
• Dabrowska MI, Becks LL, Lelli JL Jr, et al. (1996). Sulfur mustard induces apoptosis and necrosis in endothelial cells. Toxicol Appl Pharmacol 141:568–83
   PubMed Web of Science ®Google Scholar
• Das SK, Mukherjee S, Smith MG, Chatterjee D. (2003). Prophylactic protection by N-acetylcysteine against the pulmonary injury induced by 2-chloroethyl ethyl sulfide, a mustard analogue. J Biochem Mol Toxicol 17:177–84
   PubMed Web of Science ®Google Scholar
• De Rosa SC, Zaretsky MD, Dubs JG, et al. (2000). N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 30:915–29
   PubMed Web of Science ®Google Scholar
• Dekhuijzen PN. (2004). Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 23:629–36
   PubMed Web of Science ®Google Scholar
• Dodd S, Dean O, Copolov DL, et al. (2008). N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 8:1955–62
   PubMed Web of Science ®Google Scholar
• Emad A, Rezaian GR. (1997). The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 112:734–8
   PubMed Web of Science ®Google Scholar
• Foroutan SA. (1997). Medical notes on the chemical warfare: Part II (in Persian). Kowsar Med J 1:159–77
   Google Scholar
• Gao X, Anderson DR, Brown AW, et al. (2011). Pathological studies on the protective effect of a macrolide antibiotic, roxithromycin, against sulfur mustard inhalation toxicity in a rat model. Toxicol Pathol 39:1056–64
   PubMed Web of Science ®Google Scholar
• Gao X, Ray R, Xiao Y, et al. (2007). Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells. BMC Cell Biol 8:17
   PubMed Web of Science ®Google Scholar
• Gao X, Ray R, Xiao Y, et al. (2010). Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes. Pulm Pharmacol Ther 23:97–106
   PubMed Web of Science ®Google Scholar
• Gao X, Ray R, Xiao Y, Ray P. (2008). Suppression of inducible nitric oxide synthase expression and nitric oxide production by macrolide antibiotics in sulfur mustard-exposed airway epithelial cells. Basic Clin Pharmacol Toxicol 103:255–61
   PubMed Web of Science ®Google Scholar
• Ghabili K, Agutter PS, Ghanei M, et al. (2011). Sulfur mustard toxicity: history, chemistry, pharmacokinetics, and pharmacodynamics. Crit Rev Toxicol 41:384–403
   PubMed Web of Science ®Google Scholar
• Ghanei M, Abolmaali K, Aslani J. (2004a). Efficacy of concomitant administration of clarithromycin and acetylcysteine in bronchiolitis obliterans in seventeen sulfur mustard-exposed patients: an open-label study. Curr Therapeut Res 65:495–504
   PubMed Web of Science ®Google Scholar
• Ghanei M, Akhlaghpoor S, Moahammad MM, Aslani J. (2004b). Tracheobronchial stenosis following sulfur mustard inhalation. Inhal Toxicol 16:845–9
   PubMed Web of Science ®Google Scholar
• Ghanei M, Ghasemzadeh M, Shohrati M. (2005a). Improvement of respiratory symptoms by long-term low-dose erythromycin in sulfur mustard exposed cases: a pilot study (in persian). J Med C B R Def 3:1–9
   Google Scholar
• Ghanei M, Khalili AR, Arab MJ, et al. (2005b). Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis. Basic Clin Pharmacol Toxicol 97:302–5
   PubMed Web of Science ®Google Scholar
• Ghanei M, Rajaeinejad M, Motiei-Langroudi R, et al. (2011). Helium:oxygen versus air:oxygen noninvasive positive-pressure ventilation in patients exposed to sulfur mustard. Heart Lung 40:e84–9
   PubMedGoogle Scholar
• Ghanei M, Shohrati M, Harandi AA, et al. (2007). Inhaled corticosteroids and long-acting beta 2-agonists in treatment of patients with chronic bronchiolitis following exposure to sulfur mustard. Inhal Toxicol 19:889–94
   PubMed Web of Science ®Google Scholar
• Ghanei M, Shohrati M, Jafari M, et al. (2008). N-acetylcysteine improves the clinical conditions of mustard gas-exposed patients with normal pulmonary function test. Basic Clin Pharmacol Toxicol 103:428–32
   PubMed Web of Science ®Google Scholar
• Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. (2000). Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22:209–21
   PubMed Web of Science ®Google Scholar
• Grassi C, Morandini GC. (1976). A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol 9:393–6
   Web of Science ®Google Scholar
• Gross CL, Innace JK, Hovatter RC, et al. (1993). Biochemical manipulation of intracellular glutathione levels influences cytotoxicity to isolated human lymphocytes by sulfur mustard. Cell Biol Toxicol 9:259–67
   PubMed Web of Science ®Google Scholar
• Heard KJ. (2008). Acetylcysteine for acetaminophen poisoning. N Engl J Med 359:285–92
   PubMed Web of Science ®Google Scholar
• Hoesel LM, Flierl MA, Niederbichler AD, et al. (2008). Ability of antioxidant liposomes to prevent acute and progressive pulmonary injury. Antioxid Redox Signal 10:973–81
   PubMed Web of Science ®Google Scholar
• Jafari M, Ghanei M. (2010). Evaluation of plasma, erythrocytes, and bronchoalveolar lavage fluid antioxidant defense system in sulfur mustard-injured patients. Clin Toxicol (Phila) 48:184–92
   PubMed Web of Science ®Google Scholar
• Ji L, Liu R, Zhang XD, et al. (2010). N-Acetylcysteine attenuates phosgene-induced acute lung injury via up-regulation of Nrf2 expression. Inhal Toxicol 22:535–42
   PubMed Web of Science ®Google Scholar
• Jones CM, Lawrence A, Wardman P, Burkitt MJ. (2003). Kinetics of superoxide scavenging by glutathione: an evaluation of its role in the removal of mitochondrial superoxide. Biochem Soc Trans 31:1337–9
   PubMed Web of Science ®Google Scholar
• Jugg B, Fairhall S, Smith A, et al. (2013). N-Acetyl-l-cysteine protects against inhaled sulfur mustard poisoning in the large swine. Clin Toxicol (Phila) 51:216–24
   PubMed Web of Science ®Google Scholar
• Kasahara K, Kita E, Maeda K, et al. (2005). Macrolide resistance of Streptococcus pneumoniae isolated during long-term macrolide therapy: difference between erythromycin and clarithromycin. J Infect Chemother 11:112–14
   PubMedGoogle Scholar
• Kehe K, Balszuweit F, Emmler J, et al. (2008). Sulfur mustard research – strategies for the development of improved medical therapy. Eplasty 10:e32
   Google Scholar
• Korkmaz A, Kunak ZI, Paredes SD, et al. (2008). The use of melatonin to combat mustard toxicity. Neuro Endocrinol Lett 29:614–19
   PubMed Web of Science ®Google Scholar
• Kumar O, Sugendran K, Vijayaraghavan R. (2001). Protective effect of various antioxidants on the toxicity of sulphur mustard administered to mice by inhalation or percutaneous routes. Chem Biol Interact 134:1–12
   PubMed Web of Science ®Google Scholar
• Lailey AF. (1997). Oral N-acetylcysteine protects against perfluoroisobutene toxicity in rats. Hum Exp Toxicol 16:212–16
   PubMed Web of Science ®Google Scholar
• Lailey AF, Hill L, Lawston IW, et al. (1991). Protection by cysteine esters against chemically induced pulmonary oedema. Biochem Pharmacol 42:S47–54
   PubMed Web of Science ®Google Scholar
• LaRowe SD, Mardikian P, Malcolm R, et al. (2006). Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 15:105–10
   PubMed Web of Science ®Google Scholar
• Liu J, Powell KL, Thames HD, MacLeod MC. (2010). Detoxication of sulfur half-mustards by nucleophilic scavengers: robust activity of thiopurines. Chem Res Toxicol 23:488–96
   PubMedGoogle Scholar
• Mardikian PN, LaRowe SD, Hedden S, et al. (2007). An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 31:389–94
   PubMed Web of Science ®Google Scholar
• McClintock SD, Hoesel LM, Das SK, et al. (2006). Attenuation of half sulfur mustard gas-induced acute lung injury in rats. J Appl Toxicol 26:126–31
   PubMed Web of Science ®Google Scholar
• McClintock SD, Till GO, Smith MG, Ward PA. (2002). Protection from half-mustard-gas-induced acute lung injury in the rat. J Appl Toxicol 22:257–62
   PubMed Web of Science ®Google Scholar
• Millea PJ. (2009). N-acetylcysteine: multiple clinical applications. Am Fam Physician 80:265–9
   PubMed Web of Science ®Google Scholar
• Mirsadraee M, Attaran D, Boskabady MH, Towhidi M. (2005). Airway hyperresponsiveness to methacholine in chemical warfare victims. Respiration 72:523–8
   PubMedGoogle Scholar
• Mukherjee S, Stone WL, Yang H, et al. (2009). Protection of half sulfur mustard gas-induced lung injury in guinea pigs by antioxidant liposomes. J Biochem Mol Toxicol 23:143–53
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Mukherjee S, Ray BK, et al. (2010). Antioxidant liposomes protect against CEES-induced lung injury by decreasing SAF-1/MAZ-mediated inflammation in the guinea pig lung. J Biochem Mol Toxicol 24:187–94
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Mukherjee S, Stone WL, et al. (2009). Role of MAPK/AP-1 signaling pathway in the protection of CEES-induced lung injury by antioxidant liposome. Toxicology 261:143–51
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Rajaratnam V, Mukherjee S, et al. (2006). Modulation of the expression of superoxide dismutase gene in lung injury by 2-chloroethyl ethyl sulfide, a mustard analog. J Biochem Mol Toxicol 20:142–9
   PubMed Web of Science ®Google Scholar
• O'Neill HC, White CW, Veress LA, et al. (2010). Treatment with the catalytic metalloporphyrin AEOL 10150 reduces inflammation and oxidative stress due to inhalation of the sulfur mustard analog 2-chloroethyl ethyl sulfide. Free Radic Biol Med 48:1188–96
   PubMed Web of Science ®Google Scholar
• Panahi Y, Ghanei M, Aslani J, Mojtahedzadeh M. (2005). The therapeutic effect of gamma interferon in chronic bronchiolitis due to mustard gas. Iran J Allergy Asthma Immunol 4:83–90
   PubMedGoogle Scholar
• Paromov V, Qui M, Yang H, et al. (2008). The influence of N-acetyl-l-cysteine on oxidative stress and nitric oxide synthesis in stimulated macrophages treated with a mustard gas analogue. BMC Cell Biol 9:33
   PubMed Web of Science ®Google Scholar
• Periti P, Mazzei T, Mini E, Novelli A. (1993). Adverse effects of macrolide antibacterials. Drug Saf 9:346–64
   PubMed Web of Science ®Google Scholar
• Poole PJ, Black PN. (2001). Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 322:1271–4
   PubMed Web of Science ®Google Scholar
• Poole PJ, Black PN. (2003). Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am J Respir Med 2:367–70
   PubMedGoogle Scholar
• Poursaleh, Z, Harandi AA, Vahedi E, Ghanei M. (2012). Treatment for sulfur mustard lung injuries; new therapeutic approaches from acute to chronic phase. Daru 20:27
   PubMed Web of Science ®Google Scholar
• Prescott L. (2005). Oral or intravenous N-acetylcysteine for acetaminophen poisoning? Ann Emerg Med 45:409–13
   PubMed Web of Science ®Google Scholar
• Rahman I, MacNee W. (2012). Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol 12:256–65
   PubMed Web of Science ®Google Scholar
• Rahman I. (2008). Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2:351–74
   PubMedGoogle Scholar
• Rahman I. (2012). Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta 1822:714–28
   PubMed Web of Science ®Google Scholar
• Rappeneau S, Baeza-Squiban A, Marano F, Calvet J. (2000). Efficient protection of human bronchial epithelial cells against sulfur and nitrogen mustard cytotoxicity using drug combinations. Toxicol Sci 58:153–60
   PubMed Web of Science ®Google Scholar
• Razavi SM, Salamati P, Harandi AA, Ghanei M. (2013). Prevention and treatment of respiratory consequences induced by sulfur mustard in Iranian casualties. Int J Prev Med 4:383–9
   PubMedGoogle Scholar
• Rowell M, Kehe K, Balszuweit F, Thiermann H. (2009). The chronic effects of sulfur mustard exposure. Toxicology 263:9–11
   PubMed Web of Science ®Google Scholar
• Saber H, Saburi A, Ghanei M. (2012). Clinical and paraclinical guidelines for management of sulfur mustard induced bronchiolitis obliterans; from bench to bedside. Inhal Toxicol 24:900–6
   PubMed Web of Science ®Google Scholar
• Saburi A, Ghanei M. (2013). Comments on “Sulfur Mustard and Respiratory Diseases,” Tang & Loke (2012) and a prepared integrated mechanism for chronic pulmonary disease from exposure to sulfur mustard. Crit Rev Toxicol 43:275–6
   PubMed Web of Science ®Google Scholar
• Sadowska AM, Verbraecken J, Darquennes K, De Backer WA. (2006). Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis 1:425–34
   PubMedGoogle Scholar
• Sadowska AM. (2012). N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease. Ther Adv Respir Dis 6:127–35
   PubMed Web of Science ®Google Scholar
• Sandilands EA, Bateman DN. 2009. Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila) 47:81–8
   PubMed Web of Science ®Google Scholar
• Särnstrand B, Jansson AH, Matuseviciene G, et al. (1999). N,N′-Diacetyl-l-cystine-the disulfide dimer of N-acetylcysteine-is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. J Pharmacol Exp Ther 88:1174–84
   Google Scholar
• Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH. (1995). Protective effects of N-acetylcysteine treatment after phosgene exposure in rabbits. Am J Respir Crit Care Med 151:768–72
   PubMed Web of Science ®Google Scholar
• Shohrati M, Aslani J, Eshraghi M, et al. (2008a). Therapeutics effect of N-acetyl cysteine on mustard gas exposed patients: evaluating clinical aspect in patients with impaired pulmonary function test. Respir Med 102:443–8
   PubMed Web of Science ®Google Scholar
• Shohrati M, Ghanei M, Shamspour N, et al. (2010). Glutathione and malondialdehyde levels in late pulmonary complications of sulfur mustard intoxication. Lung 188:77–83
   PubMed Web of Science ®Google Scholar
• Shohrati M, Ghanei M, Shamspour N, Jafari M. (2008b). Activity and function in lung injuries due to sulphur mustard. Biomarkers 13:728–33
   PubMed Web of Science ®Google Scholar
• Stey C, Steurer J, Bachmann S, et al. (2000). The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 16:253–62
   PubMed Web of Science ®Google Scholar
• Tamaoki J, Takeyama K, Tagaya E, Konno K. (1995). Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 39:1688–90
   PubMed Web of Science ®Google Scholar
• Tang FR, Loke WK. (2012). Sulfur mustard and respiratory diseases. Crit Rev Toxicol 42:688–702
   PubMed Web of Science ®Google Scholar
• Tramper-Stranders GA, Wolfs TF, Fleer A, et al. (2007). Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 26:8–12
   PubMed Web of Science ®Google Scholar
• Weinberger B, Laskin JD, Sunil VR, et al. (2011). Sulfur mustard-induced pulmonary injury: therapeutic approaches to mitigating toxicity. Pulm Pharmacol Ther 24:92–9
   PubMed Web of Science ®Google Scholar
• Wilde PE, Upshall DG. (1994). Cysteine esters protect cultured rodent lung slices from sulphur mustard. Hum Exp Toxicol 13:743–8
   PubMed Web of Science ®Google Scholar
• Yaren H, Mollaoglu H, Kurt B, et al. (2007). Lung toxicity of nitrogen mustard may be mediated by nitric oxide and peroxynitrite in rats. Res Vet Sci 83:116–22
   PubMed Web of Science ®Google Scholar